Kyverna Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kyverna Therapeutics, Inc. (KYTX) on July 8, 2026. The report details an amendment to a Material Definitive Agreement regarding a loan facility entered into previously on October 31, 2025.
Key Financial Metrics and Debt Structure
The filing focuses on the Company's debt obligations under a non-dilutive term loan facility with an aggregate principal amount of up to $150.0 million. As of the filing date, the Company had drawn $25.0 million from the Term A tranche on November 3, 2025. The remaining $15.0 million of Term A Loans was subject to an extension.
- Total Facility Size: Up to $150.0 million.
- Term A Loans: Up to $40.0 million total; $25.0 million drawn; $15.0 million remaining.
- Term B Loans: $5.0 million to $20.0 million (milestone-based).
- Term C Loans: Up to $40.0 million (milestone-based).
- Amendment Fee: $187,500 upfront cash fee paid to extend Term A availability.
Material Changes and Agreement Amendments
Effective June 30, 2026, the Company amended its Loan and Security Agreement with Oxford Finance LLC and other lenders. The primary changes include:
- Extension of Term A: The availability of the remaining $15.0 million of Term A Loans was extended from June 30, 2026, to December 31, 2026.
- Non-Utilization Fee: If the full remaining $15.0 million of Term A is not drawn by December 31, 2026, the Company must pay a fee equal to 1.0% of the undrawn amount.
- Contingent Modifications: If the Company draws the full remaining $15.0 million of Term A, further modifications will take effect, including extensions for Term B and Term C draw periods and revised revenue covenant start dates.
Outlook, Risks, and Covenants
The Company remains subject to minimum revenue covenants beginning with the quarter ending June 30, 2027, subject to cash and market capitalization exceptions. The timing of these covenants may shift to September 30, 2027, or December 31, 2027, depending on future capital raises and the full drawdown of Term A loans.
Risks: Failure to draw the remaining Term A funds by the new deadline will trigger a non-utilization fee. Additionally, the Company must achieve specific clinical and revenue milestones to access Term B and Term C funding.
Investor Verification Checklist
- Verify the full text of the Amendment to the Loan and Security Agreement, which is expected to be filed with the Form 10-Q for the quarter ended June 30, 2026.
- Confirm whether the Company has drawn the remaining $15.0 million of Term A Loans by December 31, 2026, to determine if contingent modifications to Term B and Term C are active.
- Monitor the Company's cash position and market capitalization to assess potential waivers for minimum revenue covenants starting in 2027.
- Review upcoming clinical and revenue milestones required to unlock the $5.0 million to $20.0 million Term B and up to $40.0 million Term C tranches.